ArticleInternational journal of oncology2017
miR-486 suppresses the development of osteosarcoma by regulating PKC-δ pathway.
Article in International journal of oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Geniposide activates the transcription of Ndufs8 and enhances PD-L1 blockade for inhibiting growth of osteosarcoma.Journal of traditional and complementary medicine · 2026Article
- Article
- Multifunctional nanomaterialsMaterials today. Bio · 2024Article
- Exosome‑delivered miR‑486‑3p inhibits the progression of osteosarcoma via sponging CircKEAP1/MARCH1 axis components.Oncology letters · 2024Article
- Downregulation of PRKCI inhibits osteosarcoma cell growth by inactivating the Akt/mTOR signaling pathway.Frontiers in oncology · 2024Article
- Novel insights into the multifaceted roles of mBiomarker research · 2023Review
- miR-486-5p expression is regulated by DNA methylation in osteosarcoma.BMC genomics · 2022Article
- Long noncoding RNA SLC9A3‑AS1 increases E2F6 expression by sponging microRNA‑486‑5p and thus facilitates the oncogenesis of nasopharyngeal carcinoma.Oncology reports · 2021Article
- Overexpression of microRNA‑486 affects the proliferation and chemosensitivity of mesothelioma cell lines by targetingInternational journal of molecular medicine · 2021Article
- lncRNA NORAD promotes the progression of osteosarcoma via targeting of miR-155-5p.Experimental and therapeutic medicine · 2021Article
- The effect of dexmedetomidine on biological behavior of osteosarcoma cells through miR-1307 expression.American journal of translational research · 2021Article
- miR-486 is involved in the pathogenesis of acute myeloid leukemia by regulating JAK-STAT signaling.Naunyn-Schmiedeberg's archives of pharmacology · 2021Article
- A Novel Predictive Model Associated with Osteosarcoma Metastasis.Cancer management and research · 2021Article
- MiRNAs as Novel Adipokines: Obesity-Related Circulating MiRNAs Influence Chemosensitivity in Cancer Patients.Non-coding RNA · 2020Review
- Analysis of miRNA-mRNA Crosstalk in Radiation-Induced Mouse Thymic Lymphomas to Identify miR-486 as a Critical Regulator by Targeting IGF2BP3 mRNA.Frontiers in oncology · 2020Article
- Elevated Expression of miR-629 Predicts a Poor Prognosis and Promotes Cell Proliferation, Migration, and Invasion of Osteosarcoma.OncoTargets and therapy · 2020Article
- miRNA signatures in childhood sarcomas and their clinical implications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019Review
- MiR-486-5p inhibits IL-22-induced epithelial-mesenchymal transition of breast cancer cell by repressing Dock1.Journal of Cancer · 2019Article
- Downregulation of miR‑486‑5p in papillary thyroid carcinoma tissue: A study based on microarray and miRNA sequencing.Molecular medicine reports · 2018Article
- PKCδ reveals a tumor promoter function by promoting cell proliferation and migration in somatotropinomas.International journal of clinical and experimental pathology · 2018Article
Corrections and comments
- Retraction · 2023-08-07Concerns/Issues about Image · Duplication of Data · Duplication of/in Image · Investigation by Third Party · Paper Mill · · see also: https://pubpeer.com/publications/D0F4C2281E8766E16E27E2C260A9C1
- Retracted
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma is one of the most highly malignant types of cancer in adolescents and young adults with a high mortality rate. Despite advances in surgery, radiation therapy and chemotherapy, the prognosis for patients with osteosarcoma has not significantly improved over the past several decades. It is necessary to find new indicators of prognosis and therapeutic targets of osteosarcoma. Through the analysis of 40 osteosarcoma tissues, we found that the expression of miR‑486 was low and the expression of PKC‑δ was high in osteosarcoma. Median survival of patients with low expression of miR-486 (30 months) was shorter than the patients with higher expression of miR‑486 (40 months). We further found that miR-486 can inhibit the targeting of PKC‑δ signaling pathways, and this inhibition can inhibit the growth and invasion of osteosarcoma cells. After transfection of miR‑486 for 24 h, the proliferation of osteosarcoma cells was inhibited by ~20%, and the migration was inhibited by ~15%. In the present investigation, we demonstrated that miR‑486 is negatively associated with the expression of PKC-δ and could regulate the development of osteosarcoma. miR-486 may be a potential target for the treatment of osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.